BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
See today's BioWorld
Home
» Acadia Sinks as ACP-104 Misses Endpoint in Schizophrenia Trial
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Acadia Sinks as ACP-104 Misses Endpoint in Schizophrenia Trial
June 17, 2008
By
Donna Young
No Comments
Shares of Acadia Pharmaceuticals Inc. plunged 43 percent Monday on news that its experimental schizophrenia drug, ACP-104, failed to meet its primary endpoint of antipsychotic efficacy in a 247-patient Phase IIb study. (BioWorld Today)
BioWorld